Return to homepagePandemic Pact

Defining innate immune signaling, viral infection susceptibility, and infection control across mammals

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 1P01AI198498-01

Grant search

Key facts

  • Disease

    Disease X
  • Start & end year

    2026
    2031
  • Known Financial Commitments (USD)

    $522,784
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    PROFESSOR Michael Gale
  • Research Location

    United States of America
  • Lead Research Institution

    UNIVERSITY OF MINNESOTA
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Project 2. Defining innate immune signaling, viral infection susceptibility, and infection control across mammals Summary The focus of Project 2 is to determine the actions of cell-intrinsic innate immunity, interferon (IFN), and viral countermeasures of innate immune evasion of virus infection across model RNA viruses and diverse mammalian species. Virus infections drive enormous evolutionary pressure on both host and virus genomes. As such, host innate immune genes are highly divergent across host and virus immune antagonist genes also vary across viruses within the same family. The innate immune system can present a significant barrier to viruses crossing into new species. This project will use data from Core B to define virus-species pairs where innate immunity presents a barrier and Core C to identify genes and pathways for evaluation in mechanistic studies. We will then evaluate mechanisms of host control of virus infection and virus success at evading these responses through two independent aims. Aim 1 will evaluate species-specific effector mechanisms of IFN actions that control virus infection and will uncover mechanisms of action using comparative analyses and measuring the stage of the virus life cycle that is targeted. Aim 2 will determine the role of viral factors of innate immune evasion which support species-specific virus infection. This aim will also establish the zoonic potential of each species for human infection. Together, Project 2 studies will reveal conserved and divergent innate immune and IFN effector mechanisms of alphavirus and flavivirus control and viral evasion across species. Our results will link to Project 1 studies to define mechanisms of viral pathogenesis and will inform consideration of therapeutic strategies for mitigating infection and disrupting zoonotic virus transmission.